Janssen Biotech, Inc.
Clinical trials sponsored by Janssen Biotech, Inc., explained in plain language.
A subsidiary of Johnson & Johnson, developing biotech therapies across multiple disease areas.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Simponi under the microscope: new registry tracks Long-Term risks in ulcerative colitis patients Results expected Dec 2026 (estimated)
-
Massive study tracks IBD drug safety in kids for years
Knowledge-focused OngoingThis study follows nearly 5,000 children with Crohn's disease, ulcerative colitis, or indeterminate colitis to monitor the long-term safety of their treatments, including the drug infliximab. Researchers collect information on side effects, disease activity, and quality of life o…
Sponsor: Janssen Biotech, Inc. • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Simponi under the microscope: new registry tracks Long-Term risks in ulcerative colitis patients
Knowledge-focused OngoingThis registry follows 535 adults with moderate-to-severe ulcerative colitis who are taking or starting Simponi. Researchers will track serious side effects like infections, cancers, and pregnancy outcomes over time. The goal is to better understand the long-term safety of this me…
Sponsor: Janssen Biotech, Inc. • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC